Sequencing Core
测序核心
基本信息
- 批准号:10619607
- 负责人:
- 金额:$ 18.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-06-15 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:ATAC-seqAntibodiesAreaBiological AssayBiologyBloodCOVID-19 vaccinationCell CountCell SeparationCell Surface ProteinsCell physiologyCellsChromatinCollectionDNADNA Sequencing FacilityDataData AnalysesDengue VirusDiseaseElementsEnhancersEpigenetic ProcessFlow CytometryFundingFutureGene Expression ProfilingGenesGenomeGenomicsGuidelinesHealthHumanHuman ResourcesImmuneImmunologyIndividualInfectionLeadLengthLibrariesMethodologyMethodsMissionMolecular ProfilingMycobacterium tuberculosisPreparationProceduresProtocols documentationPublicationsRNARNA analysisRNA libraryReproducibilityResearch PersonnelResolutionRoleSARS-CoV-2 infectionSamplingServicesSiteSmall RNASortingStainsStandardizationT cell receptor repertoire sequencingT memory cellT-Cell ReceptorT-LymphocyteT-Lymphocyte SubsetsT-cell receptor repertoireTechnologyTissuesTrainingTransposaseTuberculosisUntranslated RNAVaccinationantibody conjugateantibody detectiondata managementdesignepigenomic profilingepigenomicsgenome-widegenomic platformhigh throughput analysisinsightinterestlung pathogenmicrogenomicsnext generation sequencingnovelpathogenpatient subsetsperipheral bloodprogramspromoterrespiratory pathogensingle cell sequencingsingle-cell RNA sequencingtranscription factortranscription factor USFtranscriptometranscriptome sequencingtranscriptomics
项目摘要
Sequencing Core Summary
The mission of the HIPC program at LJI is to use hypothesis-free approaches to define comprehensive molecular
profiles of T cell subsets in the context of lung pathogens. The areas of interest cover an extremely wide spectrum
of “omics” analysis including: (i) analysis of global gene expression (bulk and single-cell RNA-seq), (ii) analysis
of T cell receptors high variable sequences repertoire by bulk or single-cell TCR-seq, (iii) analysis of changes in
global epigenetics profiles (genome-wide enhancer profiles) using single-cell ATAC-seq, in T cell memory
subsets from patients infected and/or vaccinated against, SARS-CoV-2, Mycobacterium tuberculosis (Mtb), and
other lung pathogens. All these “omics” applications rely on standardized and well-validated high-throughput
Next-Generation Sequencing (NGS) methods – a key service provided by this Core.
The Sequencing Core will support all NGS activities for all the three projects involved in this program. This will
be facilitated by the extensive genomics expertise of its personnel and the availability of cutting-edge
technologies and automated platforms to generate highly reproducible and robust sequencing data from a large
number of samples. Practically, the Sequencing Core will interface directly with all three Projects and provide a
standardized and quality-controlled pipeline consisting of receiving samples, sorting cells, preparing RNA/DNA,
preparing libraries for high-throughput NGS, and transferring the resulting data to the Data Management and
Analysis Core for subsequent analysis.
测序核心摘要
LJI重债穷国计划的使命是使用无假设的方法来定义全面的分子
在肺病原体的背景下的T细胞亚群的概况。感兴趣的领域涵盖了极其广泛的范围
“组学”分析包括:(i)分析整体基因表达(批量和单细胞RNA-seq),(ii)分析
(iii)通过批量或单细胞TCR-seq分析T细胞受体高可变序列库的变化,
在T细胞记忆中使用单细胞ATAC-seq的全局表观遗传学特征(全基因组增强子特征)
来自感染和/或接种SARS-CoV-2、结核分枝杆菌(Mtb)和
其他肺部病原体。所有这些“组学”应用都依赖于标准化和经过良好验证的高通量
下一代测序(NGS)方法-该核心提供的关键服务。
测序核心将支持该计划涉及的所有三个项目的所有NGS活动。这将
通过其人员的广泛基因组学专业知识和尖端技术的可用性,
技术和自动化平台,从大规模的
样本数。实际上,测序核心将直接与所有三个项目接口,并提供一个
标准化和质量控制的管道,包括接收样品、分选细胞、制备RNA/DNA、
为高通量NGS准备库,并将结果数据传输到数据管理部门,
用于后续分析的分析核心。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gregory Seumois其他文献
Gregory Seumois的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gregory Seumois', 18)}}的其他基金
A novel CD4+ T cell subset associated with allergy protection
与过敏保护相关的新型 CD4 T 细胞亚群
- 批准号:
10742709 - 财政年份:2023
- 资助金额:
$ 18.94万 - 项目类别:
Role of a Novel Interferon Responsive T Cell Subset in Allergy and Asthma
新型干扰素反应性 T 细胞亚群在过敏和哮喘中的作用
- 批准号:
10708060 - 财政年份:2022
- 资助金额:
$ 18.94万 - 项目类别:
Role of a Novel Interferon Responsive T Cell Subset in Allergy and Asthma
新型干扰素反应性 T 细胞亚群在过敏和哮喘中的作用
- 批准号:
10588108 - 财政年份:2022
- 资助金额:
$ 18.94万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 18.94万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 18.94万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 18.94万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 18.94万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 18.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 18.94万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 18.94万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 18.94万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 18.94万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 18.94万 - 项目类别:














{{item.name}}会员




